Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Our team, comprised of seasoned professionals, collaborates with researchers to efficiently conduct PARP studies, exploring innovative approaches for both diagnosis and treatment.
Customized Solutions
Confidentiality and Data Security
Alfa Cytology specializes in developing small molecule PARP inhibitors for the treatment of a wide range of diseases.
Alfa Cytology provides dual-target PARP inhibitor development services for overcoming drug resistance and adverse effects.
Alfa Cytology collaborates with our customers to develop novel PARP degrader molecules.
Alfa Cytology specializes in the synthesis and preliminary evaluation of new PARP-targeting inhibitor prodrugs.
Alfa Cytology provides PARP peptide inhibitor development services for the treatment of a wide range of diseases.
Alpha Cytology offers you diagnostic development services for PARP.
Explore our solutions to gain insight into the role of PARP in different diseases.
Explore our services focused on understanding and addressing cancers...
Explore our services focused on understanding and addressing nervous system diseases...
Explore our services focused on understanding and addressing metabolic diseases...
Explore our services focused on understanding and addressing inflammation...
Explore our services focused on understanding and addressing sepsis...
Explore our services focused on understanding and addressing cardiovascular disorders...
Advanced experimental equipment.
Professional and well-trained core technical team.
Available 24 hours a day, 7 days a week.
Strict quality control system.
We offer recombinant proteins for various PARP isoforms, such as PARP1, PARP2, and PARP3, to meet your needs in PARP-related research.
We provide both monoclonal and polyclonal antibodies targeting different PARP isoforms, including PARP1, PARP2, and PARP3.
We offer siRNA and shRNA products targeting PARP genes, which can effectively knockdown PARP expression at the cellular level.
We provide a series of PARP activity assay kits, which can conveniently and quickly measure the enzyme activity in cell or tissue samples.
These PARP inhibitors can be used in in vitro and in vivo PARP-related disease models, providing important tools for the development of PARP-targeted therapies.
